Quantbot Technologies LP Invests $1.90 Million in Bristol Myers Squibb Company $BMY

Key Points

• Quantbot Technologies purchased 33,000 Bristol Myers Squibb shares worth approximately $1.90 million in the second quarter. Institutional investors collectively own 76.41% of BMY.
• Analyst sentiment is positive overall, with a consensus “Moderate Buy” rating and an average price target of $66.06; recent coverage included new Buy and Strong Buy ratings.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company also paid a quarterly dividend of $0.63, representing a 3.7% annualized yield.

Quantbot Technologies LP purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 33,000 shares of the biopharmaceutical company's stock, valued at approximately $1,901,000.

Several other institutional investors have also added to or reduced their stakes in the company. Life Cycle Investment Partners Ltd bought a new position in Bristol Myers Squibb in the 4th quarter worth $34,406,000. Lazard Asset Management LLC boosted its stake in shares of Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock valued at $116,693,000 after purchasing an additional 368,193 shares in the last quarter. Axxcess Wealth Management LLC increased its position in shares of Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company's stock valued at $5,322,000 after buying an additional 21,196 shares during the period. BlackRock Inc. increased its position in shares of Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the period. Finally, Asset One Wealth Management LLC bought a new position in Bristol Myers Squibb in the fourth quarter worth about $4,075,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

BMY has been the topic of several research reports. Citigroup reaffirmed a "neutral" rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. TD Cowen started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating for the company. Royal Bank Of Canada lifted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "sector perform" rating in a research report on Friday, July 31st. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Finally, Raymond James Financial initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "strong-buy" rating for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Stock Up 0.4%

Shares of NYSE:BMY opened at $67.30 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a fifty day simple moving average of $60.77 and a two-hundred day simple moving average of $59.47. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The stock has a market capitalization of $137.47 billion, a price-to-earnings ratio of 14.82, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts' expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company's quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.7%. Bristol Myers Squibb's payout ratio is 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source